Screener
Aurinia Pharmaceuticals AUPH Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of investments | (150,805) | (237,411) |
| Net cash and cash equivalents acquired in acquisition of Kezar | 5,212 | — |
| Purchases of property, equipment and intangible assets | (39) | (115) |
| Cash flows from investing activities | 63,368 | 17,759 |
| Cash flows from financing activities: | ||
| Purchase of common shares under Share Repurchase Plan | (74,880) | (89,485) |
| Payments of principal portion of Monoplant finance lease liability | (7,058) | (6,201) |
| Proceeds from issuance of common shares for equity awards | 59,154 | 10,590 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's investing cash flow?
- Aurinia Pharmaceuticals (AUPH) reported investing cash flow of $81.45M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Aurinia Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude